Abraham Scaria
Directeur Technique/Scientifique/R&D chez APPLIED GENETIC TECHNOLOGIES CORPORATION
Profil
Abraham Scaria is currently the Chief Scientific Officer at Beacon Therapeutics (USA), Inc. He previously worked as the Senior Scientific Director-Gene Therapy at Genzyme Corp., Chief Scientific Officer at IVERIC bio, Inc., Head-Gene Therapy Research at Sanofi Corp., and Vice President & Head-Ophthalmology at Casebia Therapeutics LLC.
Scaria received a graduate degree from the University of Mumbai and a doctorate degree from The Indiana University School of Medicine.
Postes actifs de Abraham Scaria
| Sociétés | Poste | Début |
|---|---|---|
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Directeur Technique/Scientifique/R&D | 15/11/2021 |
Anciens postes connus de Abraham Scaria
| Sociétés | Poste | Fin |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Casebia Therapeutics LLC
 Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC discovers, develops, and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders and autoimmune disease. The joint venture company is based in Cambridge, MA. | Corporate Officer/Principal | - |
| Sanofi Corp. | Corporate Officer/Principal | - |
| IVERIC BIO, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Abraham Scaria
| The Indiana University School of Medicine | Doctorate Degree |
| University of Mumbai | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Casebia Therapeutics LLC
Casebia Therapeutics LLC Pharmaceuticals: GenericHealth Technology Casebia Therapeutics LLC discovers, develops, and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders and autoimmune disease. The joint venture company is based in Cambridge, MA. | Health Technology |
| Sanofi Corp. | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
